Pfizer’s new monthly obesity shot: Same side‑effects as Wegovy, maybe same results?
Posted by liam_sleepnerd in Weight Loss & Metabolic - 3 points, 0 comments.
A Reuters piece reports that Pfizer’s experimental monthly obesity shot shows a side‑effect profile that mirrors Wegovy’s during its mid‑stage trial, with nausea and GI upset common to both. The study involved limited participants and focused on tolerability rather than efficacy data, but the comparison to the well‑known semaglutide formulation is striking.
From my own experience with Wegovy, the nausea curve and slow dose‑titration plan shaped my compliance. Seeing that Pfizer’s version may hit the same bump suggests the underlying GLP‑1 pathway is driving both, not just a brand difference. However, the article downplays the long‑term data and doesn’t address injection frequency or cost, which mattered in my own protocol. I’m curious if the monthly schedule will improve adherence or if it will simply shift the nausea period.
Will the monthly shot keep users on track as effectively as the weekly Wegovy, or will the side‑effects push people to drop out sooner?
Community discussion - research and educational context only. Not medical advice.